DK595889A - Laegemiddel med foroeget oploesningshastighed og indeholdende et baerestof samt fremgangsmaade til fremstilling af et saadant laegemiddel - Google Patents

Laegemiddel med foroeget oploesningshastighed og indeholdende et baerestof samt fremgangsmaade til fremstilling af et saadant laegemiddel

Info

Publication number
DK595889A
DK595889A DK595889A DK595889A DK595889A DK 595889 A DK595889 A DK 595889A DK 595889 A DK595889 A DK 595889A DK 595889 A DK595889 A DK 595889A DK 595889 A DK595889 A DK 595889A
Authority
DK
Denmark
Prior art keywords
medicinal
procedure
preparation
increased solution
solution rate
Prior art date
Application number
DK595889A
Other languages
English (en)
Other versions
DK175684B1 (da
DK595889D0 (da
Inventor
Mara Lucia Lovrecich
Original Assignee
Vectorpharma Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vectorpharma Int filed Critical Vectorpharma Int
Publication of DK595889D0 publication Critical patent/DK595889D0/da
Publication of DK595889A publication Critical patent/DK595889A/da
Application granted granted Critical
Publication of DK175684B1 publication Critical patent/DK175684B1/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/797—Lipid particle
    • Y10S977/798—Lipid particle having internalized material
    • Y10S977/799—Containing biological material
    • Y10S977/801—Drug
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nanotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Electroluminescent Light Sources (AREA)
  • Control Of El Displays (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK198905958A 1988-11-28 1989-11-27 Lægemiddel med forøget opløsningshastighed og indeholdende et bærestof samt fremgangsmåde til fremstilling af et sådant lægemiddel DK175684B1 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2277088 1988-11-28
IT8822770A IT1227626B (it) 1988-11-28 1988-11-28 Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione

Publications (3)

Publication Number Publication Date
DK595889D0 DK595889D0 (da) 1989-11-27
DK595889A true DK595889A (da) 1990-05-29
DK175684B1 DK175684B1 (da) 2005-01-17

Family

ID=11200272

Family Applications (1)

Application Number Title Priority Date Filing Date
DK198905958A DK175684B1 (da) 1988-11-28 1989-11-27 Lægemiddel med forøget opløsningshastighed og indeholdende et bærestof samt fremgangsmåde til fremstilling af et sådant lægemiddel

Country Status (16)

Country Link
US (2) US5354560A (da)
EP (1) EP0371431B1 (da)
JP (1) JP2823170B2 (da)
KR (1) KR900007398A (da)
AT (1) ATE123940T1 (da)
CA (1) CA2004064C (da)
DE (1) DE68923157T2 (da)
DK (1) DK175684B1 (da)
ES (1) ES2076192T3 (da)
FI (1) FI895693A0 (da)
HU (1) HU203468B (da)
IL (1) IL92454A (da)
IT (1) IT1227626B (da)
PT (1) PT92416B (da)
RU (2) RU1837868C (da)
YU (1) YU221189A (da)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5569469A (en) * 1984-10-16 1996-10-29 Vectorpharma International, S.P.A. Poorly soluble medicaments supported on polymer substances in a form suitable for increasing their dissolving rate
IT1241088B (it) * 1990-03-27 1993-12-29 Chiesi Farma Spa Procedimento per la preparazione di complessi piroxicam/ciclodestrina,prodotti ottenuti e loro composizioni farmaceutiche
HU210921B (en) * 1990-03-28 1995-09-28 Chinoin Gyogyszer Es Vegyeszet Process for preparing inclusion complexes of n-ethoxycarbonyl-3-morpholino-sydnonimine formed with cyclodextrines and pharmaceutical compositions containing them
IT1246188B (it) * 1990-07-27 1994-11-16 Resa Farma Procedimento per la preparazione di composizioni farmaceutiche aventi aumentata velocita' di dissoluzione della sostanza attiva e composizioni ottenute.
IT1243745B (it) * 1990-10-17 1994-06-21 Vectorpharma Int Composizioni terapeutiche transdermali contenenti farmaco e/o agente promotore dell'assorbimento cutaneo supportato su particelle microporose e microsfere polimeriche e loro preparazione.
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5552160A (en) * 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
EP1004318A3 (en) * 1991-06-21 2002-08-07 Takeda Chemical Industries, Ltd. Cyclodextrin composition
WO1993025190A1 (en) * 1992-06-10 1993-12-23 Eastman Kodak Company Surface modified nsaid nanoparticles
IT1255462B (it) * 1992-07-28 1995-11-02 Grazia Maffione Metodo di preparazione di composti di inclusione di nimesulide con ciclodestrine
AU660852B2 (en) * 1992-11-25 1995-07-06 Elan Pharma International Limited Method of grinding pharmaceutical substances
HU213200B (en) 1993-05-12 1997-03-28 Chinoin Gyogyszer Es Vegyeszet The cyclodextrin or cyclodextrin derivative cluster complexes of taxol, taxotere, or taxus, pharmaceutical preparations containing them and process for their production
GB9316580D0 (en) * 1993-08-10 1993-09-29 Smithkline Beecham Plc Pharmaceutical composition
TW384224B (en) * 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
US5684121A (en) * 1994-12-06 1997-11-04 Isp Investments Inc. N-vinyl lactam polymer containing tablets of low friability and high rate of dissolution
US5759577A (en) * 1995-01-17 1998-06-02 American Home Products Corporation Controlled release of steroids from sugar coatings
US5547948A (en) * 1995-01-17 1996-08-20 American Home Products Corporation Controlled release of steroids from sugar coatings
US5518738A (en) * 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
US5612053A (en) * 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
US6348469B1 (en) 1995-04-14 2002-02-19 Pharma Pass Llc Solid compositions containing glipizide and polyethylene oxide
WO1996032931A2 (en) * 1995-04-20 1996-10-24 Vectorpharma International S.P.A. Composite with sodium starch glycolate as a support material and products thereof
US20050267302A1 (en) * 1995-12-11 2005-12-01 G.D. Searle & Co. Eplerenone crystalline form exhibiting enhanced dissolution rate
US5686133A (en) * 1996-01-31 1997-11-11 Port Systems, L.L.C. Water soluble pharmaceutical coating and method for producing coated pharmaceuticals
HUP9600758A2 (en) * 1996-03-27 1998-03-02 Cyclolab Ciklodextrin Kutato F Diclofenac composition of diminished gastrointestinal irritation and enhanced biological resorption
US6048547A (en) * 1996-04-15 2000-04-11 Seth; Pawan Process for manufacturing solid compositions containing polyethylene oxide and an active ingredient
WO1997039761A1 (en) 1996-04-19 1997-10-30 Alpha Therapeutic Corporation A process for viral inactivation of lyophilized blood proteins
FR2757397B1 (fr) * 1996-12-23 1999-03-05 Mazal Pharma Composition pharmaceutique a base de rheine ou de diacerheine a biodisponibilite amelioree
US20050004049A1 (en) * 1997-03-11 2005-01-06 Elan Pharma International Limited Novel griseofulvin compositions
US20070141181A1 (en) 1998-02-13 2007-06-21 Nutramax Laboratories, Inc. Use of anabolic agents, anti-catabolic agents, antioxidant agents, and analgesics for protection, treatment and repair of connective tissues in humans and animals
US6797289B2 (en) 1998-02-13 2004-09-28 Nutramax Laboratories, Inc. Use of anabolic agents, anti-catabolic agents, antioxidant agents, and analgesics for protection, treatment and repair of connective tissues in humans and animals
US6451771B1 (en) 1999-02-12 2002-09-17 Nutramax Laboratories, Inc. Use of anabolic agents anti-catabolic agents and antioxidant agents for protection treatment and repair of connective tissues in humans and animals
US6086242A (en) * 1998-02-27 2000-07-11 University Of Utah Dual drive planetary mill
US6197347B1 (en) 1998-06-29 2001-03-06 Andrx Pharmaceuticals, Inc. Oral dosage for the controlled release of analgesic
US6524620B2 (en) 1998-07-20 2003-02-25 Andrx Pharmaceuticals, Inc. Diltiazem controlled release formulation and method of manufacture
FR2786100B1 (fr) * 1998-11-24 2002-03-01 Aventis Laboratoire Nouvelle application therapeutique de la nicergoline
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
US6264981B1 (en) 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
UA74539C2 (en) 1999-12-08 2006-01-16 Pharmacia Corp Crystalline polymorphous forms of celecoxib (variants), a method for the preparation thereof (variants), a pharmaceutical composition (variants)
JP2003523954A (ja) * 1999-12-08 2003-08-12 ファルマシア コーポレイション 治療効果が迅速に開始されるシクロオキシゲナーゼ−２阻害剤組成物
CN100413881C (zh) * 1999-12-08 2008-08-27 法马西亚公司 依匹乐酮晶形
US20030083493A1 (en) * 1999-12-08 2003-05-01 Barton Kathleen P. Eplerenone drug substance having high phase purity
US20060153914A1 (en) * 1999-12-10 2006-07-13 Biovail Laboratories International S.R.L. Chronotherapeutic diltiazem formulations and the administration thereof
US7108866B1 (en) 1999-12-10 2006-09-19 Biovall Laboratories International Srl Chronotherapeutic diltiazem formulations and the administration thereof
MY120279A (en) * 2000-05-26 2005-09-30 Pharmacia Corp Use of a celecoxib composition for fast pain relief
US20020146409A1 (en) * 2001-01-30 2002-10-10 Herring Steven W. Methods for stabilizing lyophilized blood proteins
PT1406633E (pt) 2001-06-18 2012-01-12 Noven Pharma Distribuição melhorada de fármacos em sistemas transdérmicos
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
BR0210519A (pt) 2001-06-22 2004-06-22 Pfizer Prod Inc Composições farmacêuticas de adsorvatos de fármaco amorfo
ES2295379T3 (es) * 2001-06-29 2008-04-16 Eurand Pharmaceuticals Ltd. Procedimiento de activacion termodinamica de medicamentos insolubles en agua cargados en polimeros reticulados.
US20030073609A1 (en) 2001-06-29 2003-04-17 Pinkerton Thomas C. Enhanced pharmacokinetic profile of intradermally delivered substances
BR0212822A (pt) * 2001-09-25 2005-08-30 Pharmacia Corp Formas cristalinas de n-(2-hidroxiacetil)-5-(4-piperdil)-4-(4-pirimidinil)-3-(4-clo rofenil)pirazol e composições farmacêuticas contendo as mesmas
BR0307344A (pt) * 2002-02-01 2004-12-14 Pfizer Prod Inc Composições farmacêuticas de dispersões amorfas de fármacos e materiais formadores de microfase lipofìlica
US20040105889A1 (en) * 2002-12-03 2004-06-03 Elan Pharma International Limited Low viscosity liquid dosage forms
US7101576B2 (en) 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
AU2003230885A1 (en) * 2002-04-12 2003-10-27 Elan Pharma International Ltd. Nanoparticulate megestrol formulations
US20100226989A1 (en) * 2002-04-12 2010-09-09 Elan Pharma International, Limited Nanoparticulate megestrol formulations
US9101540B2 (en) 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
ITMI20021074A1 (it) * 2002-05-20 2003-11-20 Actimex S R L Composizione ternaria comprendente una sostanza attiva e processo di comacinazione per la sua preparazione
UY27939A1 (es) 2002-08-21 2004-03-31 Glaxo Group Ltd Compuestos
DE10259640A1 (de) * 2002-12-18 2004-07-08 Hager & Werken Gmbh & Co Kg Einfärbemittel zur Sichtbarmachung von Plaque-Bildung auf Zähnen sowie Verfahren zur Herstellung eines solchen Einfärbemittels
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
US10172810B2 (en) 2003-02-24 2019-01-08 Pharmaceutical Productions, Inc. Transmucosal ketamine delivery composition
EP1599186B1 (en) 2003-02-24 2013-04-10 Pharmaceutical Productions Inc. Transmucosal drug delivery system
US9358296B2 (en) 2003-02-24 2016-06-07 Pharmaceutical Productions Inc. Transmucosal drug delivery system
US9498454B2 (en) 2003-02-24 2016-11-22 Pharmaceutical Productions Inc. Transmucosal drug delivery system
US9254294B2 (en) 2003-02-24 2016-02-09 Pharmaceutical Productions Inc. Transmucosal hormone delivery system
US20060141038A1 (en) * 2003-06-27 2006-06-29 Bioprogress S. P. A. Composite product obtainable by cogrinding of a active principle with a copolymer n-vinyl-2 pyrrolidone/vinyl-acetate
RS20060035A (en) 2003-07-22 2008-08-07 Arena Pharmaceuticals Inc., Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
WO2005011635A2 (en) 2003-08-04 2005-02-10 Pfizer Products Inc. Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials
BRPI0612665A2 (pt) * 2005-06-22 2010-11-30 Elan Pharma Int Ltd formulações nanoparticuladas de megestrol
KR20090010953A (ko) * 2006-03-28 2009-01-30 자블린 파머슈티칼스 인코포레이티드 저 복용량의 비-스테로이드성 항염증성 약물 및 베타-사이클로덱스트린 제형
KR20170123724A (ko) 2006-03-28 2017-11-08 자블린 파머슈티칼스 인코포레이티드 저 투여량의 디클로페낙 및 베타-사이클로덱스트린 제형
AU2016203251B2 (en) * 2006-06-30 2017-11-16 Iceutica Pty Ltd Methods for the Preparation of Biologically Active Compounds in Nanoparticle Form
IN2014MN00380A (da) * 2006-06-30 2015-06-19 Iceutica Pty Ltd
CL2007002689A1 (es) 2006-09-18 2008-04-18 Vitae Pharmaceuticals Inc Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
TWI415845B (zh) 2006-10-03 2013-11-21 Arena Pharm Inc 用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物
JP5393677B2 (ja) 2007-08-15 2014-01-22 アリーナ ファーマシューティカルズ， インコーポレイテッド ５−ＨＴ２Ａセロトニン受容体に関連した障害の治療のための５−ＨＴ２Ａセロトニン受容体のモジュレーターとしてのイミダゾ［１，２−ａ］ピリジン誘導体
EP3207921A1 (en) * 2007-09-14 2017-08-23 Wockhardt Limited Rhein or diacerein compositions
US20100285114A1 (en) * 2007-09-27 2010-11-11 Rahul Dabre Pharmaceutical compositions of rhein or diacerein
CA2926563A1 (en) * 2007-09-27 2009-04-02 Wockhardt Research Centre Pharmaceutical compositions of rhein or diacerein
WO2009048940A2 (en) * 2007-10-08 2009-04-16 Dr. Reddy's Laboratories Ltd. Diacerein pharmaceutical formulations
US8642062B2 (en) 2007-10-31 2014-02-04 Abbott Cardiovascular Systems Inc. Implantable device having a slow dissolving polymer
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
KR20110110097A (ko) * 2008-10-28 2011-10-06 에이전시 포 사이언스, 테크놀로지 앤드 리서치 수난용성 성분을 위한 메조포러스 물질 부형제
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
RS57110B1 (sr) 2008-10-28 2018-06-29 Arena Pharm Inc Sastavi modulatora 5-ht2a serotoninskog receptora korisni za tretiranje poremećaja povezanih sa njim
US7828996B1 (en) 2009-03-27 2010-11-09 Abbott Cardiovascular Systems Inc. Method for the manufacture of stable, nano-sized particles
DK2421513T3 (da) 2009-04-24 2018-03-26 Iceutica Pty Ltd Hidtil ukendt formulering med indomethacin
EP2442643A4 (en) * 2009-06-17 2014-08-06 Isp Investments Inc PROCESS FOR THE PREPARATION OF STABLE, MICROENCAPSULATED AND SLOWLY RELEASED BIOCIDAL ACTIVE SUBSTANCES AND RELATED COMPOSITION
AR077692A1 (es) 2009-08-06 2011-09-14 Vitae Pharmaceuticals Inc Sales de 2-((r)-(3-clorofenil) ((r)-1-((s) -2-(metilamino)-3-((r)-tetrahidro-2h-piran-3-il) propilcarbamoil) piperidin -3-il) metoxi) etilcarbamato de metilo
JP5870775B2 (ja) * 2011-05-11 2016-03-01 ライオン株式会社 錠剤及びその製造方法
WO2013016156A1 (en) 2011-07-22 2013-01-31 Glaxo Group Limited Polymorphic forms of the sodium salt of 4-tert- butyl -n-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzene sulfonamide
DK2748146T3 (da) 2011-07-22 2017-05-22 Chemocentryx Inc Krystallinsk form af natriumsaltet af 4-tert-butyl-n-[4-chlor-2-(1-oxy-pyridin-4-carbonyl)-phenyl]-benzensulfonamid
KR101378951B1 (ko) * 2011-07-29 2014-03-31 재단법인 유타 인하 디디에스 및 신의료기술개발 공동연구소 생체이용률이 향상된 초산 메게스트롤 분말을 포함하는 경구투여용 제제 및 이의 제조방법
MY172885A (en) 2011-09-01 2019-12-13 Glaxo Group Ltd Novel crystal form
WO2013032310A1 (ko) * 2011-09-02 2013-03-07 재단법인 유타 인하 디디에스 및 신의료기술개발 공동연구소 메게스트롤 속붕해정 및 이의 제조 방법
EP2793856B1 (en) * 2011-12-23 2015-12-16 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Orally-disintegrating formulations of flurbiprofen
EP2797583B1 (en) * 2011-12-27 2015-09-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Combined pharmaceutical formulation containing diacerein
ITMI20120092A1 (it) 2012-01-26 2013-07-27 Micro Macinazione S A Compositi di inclusione farmaco-carrier preparati con processo di attivazione meccano-chimica mediante mulini a getto di fluido ad alta energia
ES2821528T3 (es) 2012-11-14 2021-04-26 Grace W R & Co Composiciones que contienen un material biológicamente activo y un óxido inorgánico no ordenado
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
CA2952567A1 (en) 2014-06-25 2015-12-30 Glaxosmithkline Intellectual Property Development Limited Crystalline salts of (s)-6-((1-acetylpiperidin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide
CN107148418A (zh) 2014-09-08 2017-09-08 葛兰素史密斯克莱知识产权发展有限公司 2‑(4‑(4‑乙氧基‑6‑氧代‑1,6‑二氢吡啶‑3‑基)‑2‑氟苯基)‑n‑(5‑(1,1,1‑三氟‑2‑甲基丙‑2‑基)异噁唑‑3‑基)乙酰胺的晶型
CN109562085A (zh) 2015-06-12 2019-04-02 阿速万科学有限责任公司 用于预防和治疗rem睡眠行为障碍的二芳基和芳基杂芳基脲衍生物
AU2016291673A1 (en) 2015-07-15 2018-01-25 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3079303A (en) * 1958-12-11 1963-02-26 Smith Kline French Lab Basic tablet granulation and process of using same
IT629516A (da) * 1959-04-30
US3328256A (en) * 1963-05-27 1967-06-27 William E Gaunt Spherical beads and their production
NL6414091A (nl) * 1964-12-04 1966-06-06 Organon Nv Werkwijze voor het vloeibaar maken van poeders alsmede de aldus verkregen poeders
JPS5132719A (en) * 1974-09-13 1976-03-19 Yoshinobu Nakai Iyakuhinnoshorihoho
US4107288A (en) * 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US4037794A (en) * 1974-09-23 1977-07-26 Dierks & Sohne Granulation apparatus
DE2742442C3 (de) * 1977-09-21 1980-03-06 Balcke-Duerr Ag, 4030 Ratingen Elastische Kupplung
JPS5849428A (ja) * 1981-09-16 1983-03-23 Takeda Chem Ind Ltd 細粒剤の製造法
EP0129893B1 (en) * 1983-06-28 1991-09-04 Takeda Chemical Industries, Ltd. Ground mixture
DE3346123A1 (de) * 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
GB8403359D0 (en) * 1984-02-08 1984-03-14 Erba Farmitalia Pharmaceutical compositions
US4837031A (en) * 1987-09-17 1989-06-06 Mallinckrodt, Inc. Compositions containing ibuprofen

Also Published As

Publication number Publication date
YU221189A (en) 1991-06-30
JP2823170B2 (ja) 1998-11-11
IT8822770A0 (it) 1988-11-28
HU203468B (en) 1991-08-28
PT92416B (pt) 1995-08-09
PT92416A (pt) 1990-05-31
DE68923157T2 (de) 1995-11-09
DE68923157D1 (de) 1995-07-27
KR900007398A (ko) 1990-06-01
DK175684B1 (da) 2005-01-17
RU2097027C1 (ru) 1997-11-27
RU1837868C (ru) 1993-08-30
HU896191D0 (en) 1990-02-28
EP0371431A3 (en) 1991-10-09
CA2004064C (en) 2000-02-08
EP0371431A2 (en) 1990-06-06
JPH02184621A (ja) 1990-07-19
US5449521A (en) 1995-09-12
IT1227626B (it) 1991-04-23
IL92454A (en) 1994-06-24
CA2004064A1 (en) 1990-05-28
ES2076192T3 (es) 1995-11-01
IL92454A0 (en) 1990-08-31
EP0371431B1 (en) 1995-06-21
FI895693A0 (fi) 1989-11-28
HUT52366A (en) 1990-07-28
DK595889D0 (da) 1989-11-27
ATE123940T1 (de) 1995-07-15
US5354560A (en) 1994-10-11

Similar Documents

Publication Publication Date Title
DK595889A (da) Laegemiddel med foroeget oploesningshastighed og indeholdende et baerestof samt fremgangsmaade til fremstilling af et saadant laegemiddel
HUT59005A (en) Process for producing transdermal pharmaceutical preparations containing 2-amino-6-(propyl-amino)-4,5,6,7-tetrahydro-benzothiazole
DK0455391T3 (da) Granulerede præparater og fremgangsmåde til fremstilling heraf
HU171717B (hu) Sposob poluchenija slozhnykh alkil'nykh ehfirov 1,4-digidropiridin-karbonovoj kisloty i lechebnykh preparatov soderzhahhikh takie soedinenija
HU175569B (hu) Insekticidy i sposob poluchenija ikh aktivnykh vehhestv, proizvodnzkh benzol i -ureido-difenil-ehfira
NO944473L (no) Sammensetninger med vedvarende frigjöring og fremgangsmåte for fremstilling av farmasöytiske sammensetninger
KR880004806A (ko) 분무 건조 아세트아미노펜
HUT43952A (en) Process for preparing pharmaceuticals comprising (-)-3-(3,4-dihydroxyphenyl)-l-alanine-methylester
DK362284D0 (da) Fremgangsmaade til fremstilling af praeparater med reguleret frigoerelse af biologisk aktive materialer og de fremstillede praeparater
HUT49113A (en) Process for producing 2-/2-hydroxy-3-phenoxy-propyl-amino/-ethyl-phenoxy-methyl-amido derivatives and pharmaceutical compositions containing them as active components
DK0391374T3 (da) Fremgangsmåde til fremstilling af farmaceutiske præparater med høj stabilitet indeholdende bromocriptin, samt hertil svarende produkter
NO157244C (no) Fremgangsmaate til fremstilling av en legemiddelform paa basis av granulat med forbedret magetaalbarhet.
SE8800080D0 (sv) Lekemedelskomposition
DE3272602D1 (en) Solid galenic form for oral administration and process for its preparation
DK330787A (da) Stabiliseret farmaceutisk sammensaetning
ES2021579B3 (es) Capsulas divisibles en piezas
ES444426A2 (es) Aparato de liofilizacion.
FR2351993A1 (fr) Composes 9-(3-o-acyl-b-d-arabinofuranosyl)adeniniques, composes 9-(2,3-di-o-acyl-b-d-arabinofuranosyl)-adeniniques, leur procede de preparation, et leur application en tant que medicaments
PT65456A (fr) Procede de preparation de dihydro-1,4 pyridines utilisables notamment comme medicaments antihypertenseurs et antiangoreux
HU173879B (hu) Sposob poluchenija proizvodnykh tetrazolil- i tetrazolilalkil-imidazola i benzimidazola i farmacepticheskikh preparatov, soderzhahhikh ehti soedinenija v kachestve aktivnykh vehhestv
DE3066874D1 (en) 1,2-bis(nicotinamido)propane, process for preparing the same and pharmaceutical composition containing the same
SE8703361L (sv) Granulaera produkter (iv)
DK0426311T3 (da) Fremgangsmåde til bearbejdning af krydderier og andet aromatisk spiseligt vegetabilsk stof
HU173463B (hu) Sposob poluchenija 1-metil-2-/fenil-oksimetil/-5-nitro-imidazola i lechebnykh preparatov soderzhahhikh takoe aktivnoe vehhestvo
HU172245B (hu) Sposob poluchenija proizvodnykh 1,4-digidro-2h-izokhinolina s osnovnym zamestitelem i lechebnykh preparatov soderzhahhikh takie akyivnye sostavljajuhhie

Legal Events

Date Code Title Description
PBP Patent lapsed

Country of ref document: DK